Sygnature Discovery announced two key executive appointments. Dr Allan Jordan and Ms Louisa Jordison have joined the organization as they continue their strong growth trajectory in the drug research market.   Allan comes on-board as director of Oncology Drug Discovery and in this new role his primary focus will be to augment Sygnature’s existing Oncology drug discovery capabilities and Cellular Biology. Allan joins Sygnature from Cancer Research UK where he worked for the past decade.  ...